Product Description
| Download Documents | |
| Product Sheet | |
| SDS | COA_Lot S513.S13.0122D |
Monomethyl auristatin F (MMAF) is a new antimitotic auristatin derivative with a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart, MMAE (references 1 & 2). This HRP-MMAF conjugate with a stable thiol ether bond is designed with similar linker chemistry as ADCs prepared by our customer using our Antibody Mc-MMAF Conjugation Kit (with VC-PAB linker) (Cat#: CM11425). This conjugate is synthesized at CellMosaic for our customer's use in horseradish peroxidase (HRP) based assays. A long flexible PEG linker is also incorporated in the conjugate to retain HRP activity and MMAF binding. The final conjugate is HPLC-purified to obtain 1:1 MMAF-labeled HRP conjugates and is lyophilized from PBS buffer containing sugar-based stabilizer for easy shipping and storage.
The product is sold as 1 vial of 0.5 mg (Cat# CM53217-0.5MG) or 4 vials of 0.5 mg (Cat# CM53217-2MG). For bulk orders, please contact us for a quote.
Application
- Assay development for the quantitation and detection of MMAF labeled biopolymers (ADC and PDC) and MMAF drug released from the conjugate.
- Indirect and competitive ELISA assay
Key Features
- Lyophilized powder and ready for usage after reconstitution with water, no need for external buffer.
- HPLC-purified single-labeled conjugate, 1:1 HRP-VC-PAB-MMAF
- Retained HRP activity, 200-300 units/mg protein (1 unit is the amount of enzyme that will form 1.0 mg purpurogallin from pyrogallol in 20s at pH 6.0 at 20°C).
- A long flexible PEG linker is incorporated to retain the HRP activity and MMAF binding.
- Amount accurately determined by UV/HPLC analysis.
Selected References
1) Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17: 114–24.
2) Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6):2358−2364.
